NCT05811247已完成3 期
Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (LunAIRo Study)
Apnimed63 个研究点 分布在 1 个国家目标入组 660 人开始时间: 2023年8月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 660
- 试验地点
- 63
- 主要终点
- Change from Baseline in Apnea-Hypopnea Index (AHI)
研究概览
简要总结
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age at the time of informed consent.
- •PSG criteria: AHI of >5; ≤ 25% central or mixed apneas; and PLM arousal index ≤15
- •PROMIS-Fatigue: raw score ≥17
- •PAP intolerance or current PAP refusal.
- •BMI between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive.
排除标准
- •Narcolepsy, restless leg syndrome, REM sleep behavior disorder
- •Insomnia disorder characterized by difficulty initiating or maintaining sleep, or use within the past month of sedative-hypnotics or other medication for the purpose of treating or avoiding insomnia symptoms.
- •Pierre Robin, Treacher Collins, or other craniofacial malformation syndrome, or grade ≥3 tonsillar hypertrophy.
- •Clinically significant cardiac disease, e.g., ventricular arrhythmia, untreated or unstable coronary artery disease, cardiac failure. Stable atrial arrhythmia is allowed.
- •Neuromuscular disorder (e.g., motor neuron disease, muscular dystrophy or myopathy, myasthenic syndrome); epilepsy; Parkinson, Alzheimer, or other neurodegenerative disease.
研究组 & 干预措施
AD109
Experimental
AD109
干预措施: AD109 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in Apnea-Hypopnea Index (AHI)
时间窗: 6 months
AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.
次要结局
未报告次要终点
研究者
研究点 (63)
Loading locations...
相似试验
已完成
3 期
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)OSANCT05813275Apnimed646
已完成
3 期
A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the KneeOsteoarthritis Pain of the KneeNCT04683627Noven Pharmaceuticals, Inc.370
已完成
3 期
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction CarcinomaNCT03777657BeiGene997
已完成
3 期
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaNCT03957590BeiGene370
招募中
3 期
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart DefectsPrimum Atrial Septal DefectAtrioventricular Septal DefectVentricular Septal DefectNCT05253209Asklepion Pharmaceuticals, LLC97